Bristol Myers vs. Eli Lilly: Is BMY’s Deep Valuation Discount Hiding an Opportunity?

insidermonkey.com · 2026-10-20

Bristol-Myers Squibb Company (NYSE:BMY) and Eli Lilly and Company (NYSE:LLY) are almost opposites in the pharmaceutical market.

TickrTrends take: Bristol Myers Squibb trades at a significant valuation discount relative to peer Eli Lilly, which TickrTrends currently assesses as overvalued based on derived metrics. A valuation-focused reader should monitor whether BMY's discount reflects genuine fundamental weakness in its Healthcare sector operations or represents a temporary market mispricing that could narrow over time. The relative positioning of both companies' valuations suggests watching for developments in pipeline progress, revenue growth, and profitability trends that could justify or further compress the valuation gap between them.

Read the full story at insidermonkey.com →